Comparative in vitro activity of gemifloxacin

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Quinolones are a class of synthetic broad-spectrum antibacterial drugs.
• Assessing the in vitro activity of new quinolones against various bacterial pathogens is crucial for understanding their therapeutic potential.

Purpose of the Study:

• To evaluate the in vitro antibacterial potency of gemifloxacin compared to other quinolones against a range of Gram-positive and Gram-negative aerobic and anaerobic bacteria.
• To determine the susceptibility of ciprofloxacin-resistant isolates to gemifloxacin and other newer quinolones.

Main Methods:

• In vitro susceptibility testing of gemifloxacin, ciprofloxacin, ofloxacin, moxifloxacin, trovafloxacin, grepafloxacin, and clinafloxacin against various bacterial species.
• Comparison of minimum inhibitory concentrations (MICs) to assess relative potency.

Main Results:

• Gemifloxacin demonstrated superior in vitro potency against Gram-positive aerobes, including streptococci and staphylococci, compared to ciprofloxacin and ofloxacin.
• A significant proportion of ciprofloxacin-resistant pneumococci and staphylococci were susceptible to gemifloxacin and other newer quinolones.
• Against Gram-negative aerobes, gemifloxacin exhibited similar or slightly lower potency than ciprofloxacin, with cross-resistance observed in resistant isolates.
• Gemifloxacin was the most potent quinolone against Gram-positive anaerobes and fusobacteria, while trovafloxacin was most potent against other Gram-negative anaerobes.

Conclusions:

• Gemifloxacin exhibits potent in vitro activity against Gram-positive bacteria, offering a promising option for infections caused by susceptible and some resistant strains.
• Its activity profile against Gram-negative aerobes suggests it may not be a primary choice for infections dominated by these pathogens.
• Further clinical evaluation is warranted to confirm the therapeutic efficacy of gemifloxacin.